Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy

Stock Information for Alterity Therapeutics Limited

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Alterity Therapeutics Limited

Alterity Therapeutics Releases Appendix 4C - Q4 FY26 Quarterly Cash Flow Report & Corporate Update
Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026
Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy
Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
Alterity Therapeutics Releases Appendix 4C - Q3 FY26 Quarterly Cash Flow Report & Corporate Update
Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.